Medgenics (LON:MEDU,AMEX:MDGN), inventor of the Biopump device for the sustained production and delivery of medicines to treat chronic diseases such as anaemia and hepatitis C, said the US Patent & Trademark Office has issued what’s called a notice of allowance.
Put simply this expands the company's scope of patent coverage for additional therapeutic proteins. Once issued,Medgenics' global portfolio will include 45 patents granted, with 79 patent applications pending.
Chief executive Andrew Pearlman: “With this allowance we have further broadened the universe of therapeutic proteins that can be delivered through our Biopump platform technology.
“We continue to build the value of our intellectual property worldwide with the knowledge that new therapeutic areas will be covered by our patent portfolio."
Shares rose 5p to 285p in London on the news
No comments:
Post a Comment